TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03374553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINI DO636
Description: MINIject 636 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant CS636 and a Delivery Tool.~The Delivery Tool is a single-use tool, designed for inserting the CS636 implant into the sub-scleral location through an ab-interno minimally-invasive approach.~For MINIject 636, there are 2 types of Delivery Tools available to implant and position the CS636 implant.~Both types of Delivery Tools are being studied in this amended study: Dual Operator Delivery Tool (DODT) and Single Operator Delivery Tool (SODT).~DODT is used in the first arm (cohort 1 - MINI DO636), SODT is used in the second arm (cohort 2 - MINI SO636).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINI SO636
Description: MINIject 636 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant CS636 and a Delivery Tool.~The Delivery Tool is a single-use tool, designed for inserting the CS636 implant into the sub-scleral location through an ab-interno minimally-invasive approach.~For MINIject 636, there are 2 types of Delivery Tools available to implant and position the CS636 implant.~Both types of Delivery Tools are being studied in this amended study: Dual Operator Delivery Tool (DODT) and Single Operator Delivery Tool (SODT).~DODT is used in the first arm (cohort 1 - MINI DO636), SODT is used in the second arm (cohort 2 - MINI SO636).
Study: NCT00484536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP323
Description: 250 mg capsules, 500 mg bid (1000 mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsules, once daily
Study: NCT04325308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protein-enriched human milk diet
Description: 1.2 g of human-based protein will be added to each 100 ml of human milk administered

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual human milk diet
Description: Human-based protein will not be added to the human milk administered.
Study: NCT00484536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP323
Description: 250 mg Capsules, 500 mg, once daily
Study: NCT04215523

Intervention type: DRUG
Intervention: Dapagliflozin
Description: Dapagliflozin dispensing claim for any dose is exposure

Intervention type: DRUG
Intervention: DPP-4 inhibitor
Description: DPP4 inhibitor dispensing claim for any dose is reference
Study: NCT02176395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danhong injection
Description: 40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
Study: NCT00316719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAM group
Description: Subjects took one LAM 100mg tablet orally once daily and one ADV placebo tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADV group
Description: Subjects took one ADV 10mg tablet orally once daily and one LAM placebo tablet orally once daily.
Study: NCT03493399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interference
Description: The principle of interference-based techniques is to move the resources allocated to the elaboration of intrusive desire thoughts to a competing task (e.g., clay modelling, competitive mental imagery, Tetris) in order to monopolize the resources underlying craving, thus preventing its elaboration and reducing its vividness and overwhelming nature. Several studies (Andrade, Pears, May, \& Kavanagh, 2012; May, Andrade, Panabokke, \& Kavanagh, 2010; Skorka-Brown, Andrade, Whalley, \& May, 2015) have shown the efficacy of such techniques to reduce substance-related craving. Yet, data obtained on clinical samples remain scarce.~Due to the flexibility of the single case design towards each participant, the list of interference-based techniques that will be used in this study cannot be exhaustive. However, the following will be proposed to participants: Tetris (smartphone version), manipulation of a bunch of keys, manipulation of a fidget, mental imagery, reading and memorizing a text.
Study: NCT01559467

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiovascular Magnetic Resonance Imaging
Description: Routine clinical care plus cardiovascular magnetic resonance imaging early in the diagnostic process
Study: NCT01814982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-17299425
Description: JNJ-17299425 will be administered at a starting dose of 1 milligram (10 milliliter of a 0.1 mg/ml solution) as intravenous bolus injection over 2 minutes in central vein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-17299425
Description: JNJ-17299425 will be administered at a starting dose of 1 milligram (10 milliliter of a 0.1 mg/ml solution) as intravenous bolus injection over 2 minutes in central vein.
Study: NCT02750969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lidoderm patch (Lidocaine 5% patch)
Description: The investigator will attach the patches on the patient's back for 12 consecutive hours.~tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tegaderm patch. (neutral patch, containing no drug)
Description: The investigator will attach the patches on the patient's back for 12 consecutive hours.~tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood test- serum lidocain levels
Description: each participant will undergo blood test. the participant's group that start the trial with the lidoderm patch and later will use the tegaderm patch will have 2 blood tests for werum lidocain level test. the group taht start the trial with the tegaderm patch and later the lidoderm patch will have only one blood test measuring lidocaine serum level.~the tubes containing the serum will be shipped abroad via an international medical cargo company for lidocaine levels tests.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood test- serum lidocain levels
Description: each participant will undergo blood test. the participant's group that start the trial with the lidoderm patch and later will use the tegaderm patch will have 2 blood tests for werum lidocain level test. the group taht start the trial with the tegaderm patch and later the lidoderm patch will have only one blood test measuring lidocaine serum level.~the tubes containing the serum will be shipped abroad via an international medical cargo company for lidocaine levels tests.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hearing tests
Description: each participant that have not done hearing test in the last 1 year previous to the trial will have one in the first day of the trial.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hearing tests
Description: each participant that have not done hearing test in the last 1 year previous to the trial will have one in the first day of the trial.
Study: NCT01067430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: Film coated tablet, 90 mg taken once a day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Enteric coated tablet 50 mg given three times a day for 14 days
Study: NCT02031406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-discharge counseling on medication adherence & literacy
Study: NCT01542970

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Olive oil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: Omega-3 PUFA treatment comprises of maternal supplementation of 3 capsules of Pikasol® (1g capsules containing 640 mg ω-3 PUFA) 2 times daily during pregnancy and lactation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Refined coconut and peanut oil without L. reuteri
Description: 2x20 drops daily to the mother from gw 20 and from birth to the child during the first year of life

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Refined coconut and peanut oil without L. reuteri
Description: 2x20 drops daily to the mother from gw 20 and from birth to the child during the first year of life

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. reuteri
Description: The L. reuteri supplementation comprises of L. reuteri suspension 109 colony forming units (CFU) in oil (refined coconut and peanut oil) (20 droplets x 2 daily) to the mothers during pregnancy and 108 CFU (5 droplets x 1) to the children during the first years of life

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. reuteri
Description: The L. reuteri supplementation comprises of L. reuteri suspension 109 colony forming units (CFU) in oil (refined coconut and peanut oil) (20 droplets x 2 daily) to the mothers during pregnancy and 108 CFU (5 droplets x 1) to the children during the first years of life
Study: NCT00862940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 10 mg tablets twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets twice daily
Study: NCT01559467

Intervention type: OTHER
Group type: OTHER
Intervention: Computed Tomography Angiography
Description: Routine clinical care plus computed tomography angiography early in the diagnostic process
Study: NCT04336306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality-based therapy (VRBT)
Description: The warm-up was performed using the Just Dance 2015 game, in a sequence previously defined in a pilot study, aiming to increase HR progressively. A multimedia projector (Epson Power Life, H309A, China) connected to a console (Xbox One KinectTM, Microsoft, Redmond, WA) was used to project the game onto a white wall.The conditioning phase was performed using the Shape Up exercise game, in which patients perform exercises following a virtual therapist.
Study: NCT03308201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay022+exemestane
Description: Part one: Hemay022 tablets will be taken orally once daily in doses of 200mg, 300mg,400mg or 500mg for 28 days in combination with exemestane.~Part two: Hemay022 tablets combination with exemestane.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay022+letrozole
Description: Part two: Hemay022 combination with letrozole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay022+ fulvestrant
Description: Part two: Hemay022 combination with fulvestrant.
Study: NCT03240484

Intervention type: DIAGNOSTIC_TEST
Intervention: X-Ray Imaging
Description: X-Ray imaging in the following positions: Lateral standing, lateral seated, standard standing AP pelvis and AP pelvis lying down.

Intervention type: DIAGNOSTIC_TEST
Intervention: X-Ray Imaging
Description: X-Ray imaging in the following positions: Lateral standing, lateral seated, standard standing AP pelvis and AP pelvis lying down.
Study: NCT02648945

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: first, Verbal Memory task was completed by each participant. Participant then started walking on the treadmill at either a speed of 3.0 mph (4.8 km/h) for sedentary individuals or 3.5 mph (5.6 km/h) for active individuals with grade 0% (Hanson, 1984). This was followed by an increase in grade of 2% for every 2 mins with the speed remaining constant until targeted HR was reached. A heart rate (HR) monitor (POLAR®) was used to measure HR throughout the test and rating of perceived exertion (RPE) was done at the end of every 2 min stage. Exercise was stopped as soon as participant reaches targeted HR or requests to stop because of fatigue or any discomfort. Participant was then given time to cool down until HR reached or fell below 120 bpm and was allowed to take a break for approximately 1 min before proceeding with the second set of Verbal Memory Task. Upon completing the memory test, the participant was allowed to leave

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: first, Verbal Memory task was completed by each participant. Participant then started walking on the treadmill at either a speed of 3.0 mph (4.8 km/h) for sedentary individuals or 3.5 mph (5.6 km/h) for active individuals with grade 0% (Hanson, 1984). This was followed by an increase in grade of 2% for every 2 mins with the speed remaining constant until targeted HR was reached. A heart rate (HR) monitor (POLAR®) was used to measure HR throughout the test and rating of perceived exertion (RPE) was done at the end of every 2 min stage. Exercise was stopped as soon as participant reaches targeted HR or requests to stop because of fatigue or any discomfort. Participant was then given time to cool down until HR reached or fell below 120 bpm and was allowed to take a break for approximately 1 min before proceeding with the second set of Verbal Memory Task. Upon completing the memory test, the participant was allowed to leave
Study: NCT03240484

Intervention type: DIAGNOSTIC_TEST
Intervention: X-Ray Imaging
Description: X-Ray imaging in the following positions: Lateral standing, lateral seated, standard standing AP pelvis and AP pelvis lying down.

Intervention type: OTHER
Intervention: Gait Analysis
Description: Certain patients may be asked to participate in a motion analysis procedure at the Human Movement Laboratory at the University of Ottawa. This procedure takes approximately 1.5 hours and you will only be asked to participate in the motion analysis procedure once. Participants will change into a custom-designed tight body suit, which has reflective markers on its surface for infrared video capture. Participants will then have pairs of surface electromyography (EMG) electrodes placed on certain areas of the skin on the legs and on the back. Wearing the EMG electrodes and marker suit, participants will perform 5 trials of walking on a level walkway, walking up and down a 3-step staircase, sitting from a standing position, and standing from a seated position.

Intervention type: OTHER
Intervention: Gait Analysis
Description: Certain patients may be asked to participate in a motion analysis procedure at the Human Movement Laboratory at the University of Ottawa. This procedure takes approximately 1.5 hours and you will only be asked to participate in the motion analysis procedure once. Participants will change into a custom-designed tight body suit, which has reflective markers on its surface for infrared video capture. Participants will then have pairs of surface electromyography (EMG) electrodes placed on certain areas of the skin on the legs and on the back. Wearing the EMG electrodes and marker suit, participants will perform 5 trials of walking on a level walkway, walking up and down a 3-step staircase, sitting from a standing position, and standing from a seated position.
Study: NCT01397162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Fluticasone propionate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching fluticasone propionate HFA MDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903
Description: BI 54903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903
Description: BI 54903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903
Description: BI 54903
Study: NCT03022136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold sensation method
Description: Complete sensory loss to ice will be evaluated form anterior median line to posterior median line at the end of surgery.
Study: NCT02975518

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Administration of radio labelled endothelial outgrowth cells
Description: Radio labelled endothelial outgrowth cells will be administered to patients undergoing elective coronary angiography and stenting. They will be administered intra-venously and intra-arterially (right radial artery) in separate arms. Migratory behaviour of these cells will be defined using PET CT. Intra-venous and intra-arterial injection of free radio tracer will serve as a control comparator arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Administration of radio labelled endothelial outgrowth cells
Description: Radio labelled endothelial outgrowth cells will be administered to patients undergoing elective coronary angiography and stenting. They will be administered intra-venously and intra-arterially (right radial artery) in separate arms. Migratory behaviour of these cells will be defined using PET CT. Intra-venous and intra-arterial injection of free radio tracer will serve as a control comparator arms.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Administration of radio labelled endothelial outgrowth cells
Description: Radio labelled endothelial outgrowth cells will be administered to patients undergoing elective coronary angiography and stenting. They will be administered intra-venously and intra-arterially (right radial artery) in separate arms. Migratory behaviour of these cells will be defined using PET CT. Intra-venous and intra-arterial injection of free radio tracer will serve as a control comparator arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Administration of radio labelled endothelial outgrowth cells
Description: Radio labelled endothelial outgrowth cells will be administered to patients undergoing elective coronary angiography and stenting. They will be administered intra-venously and intra-arterially (right radial artery) in separate arms. Migratory behaviour of these cells will be defined using PET CT. Intra-venous and intra-arterial injection of free radio tracer will serve as a control comparator arms.
Study: NCT04511546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BPET Prototype Scan
Description: Scan on the BPET Prototype PET system and qualitative comparison with a PET image acquired on a conventional clinical PET system.
Study: NCT00962910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFF evidence based pathway
Description: A care pathway, as complex intervention, will be implemented.
Study: NCT03959943

Intervention type: PROCEDURE
Intervention: Sensory nerve coaptation
Description: A recipient sensory nerve branch of the lateral cutaneous femoral nerve (LCFN) was reattached to a donor nerve in the chest area. The anterior cutaneous branch of the second or third intercostal nerve was used as the donor nerve. Direct, end-to-end nerve coaptation was performed.
Study: NCT03980041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-549 (eganelisib)
Description: IPI-549 (40mg QD) administered orally in 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (480mg Q4W) administered intravenously (IV) in 28-day cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab (480mg Q4W) administered intravenously (IV) in 28-day cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Placebo administered orally in 28-day cycles
Study: NCT02793921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Aerobic Exercise Intervention
Description: The intervention is moderate-intensity aerobic exercise. Walking on a motorized treadmill will be the encouraged mode of exercise; however participants may use other equipment or home exercise. Participants will begin by exercising 10-15 minutes for 3 days/week during the first 2 weeks and gradually increase the duration for the following 4 weeks until they reach 40-50 minutes per session/3 days per week. This level is then maintained for the remainder of the 6 months. The rate of increase will be tailored based on baseline cardiorespiratory fitness and response to exercise. All sessions start and end with a vital sign check (in-person) and 5-10 minutes warm-up/cool-down. Trained exercise physiologists will supervise all exercise sessions and closely monitor adherence, intensity, and safety when sessions are completed in-person, or through regular communication when home-based exercise is warranted (due to COVID-19).
Study: NCT00808860

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GP group
Description: Gliclazide MR 30mg once a day, orally Gynostemma pentaphyllum tea 3 grams twice daily, orally

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Gliclazide MR 30mg once a day, orally Placebo tea 3 grams twice daily, orally
Study: NCT03777774

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Passive Redon subgaleal drains
Description: Passive non-vacuum subgaleal drains will be placed during closing stage of craniectomy. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum Redon subgaleal drains
Description: Active vacuum subgaleal drains will be placed during the closing stage of craniectomy. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No Redon subgaleal drains
Description: A subgaleal drain will be placed during the closing stage of craniectomy but it will be clamped. The drain will be unclamped if necessary. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
Study: NCT00957554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irbesartan/amlodipine
Description: Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irbesartan
Description: Pharmaceutical form: 150 and 300 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily
Study: NCT00354744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dactinomycin
Description: Age based dosage: ≥ 1 year 0.045 mg/kg IV x 1(maximum dose 2.5 mg), \< 1 year 0.025 mg/kg.~Day 1 of Weeks 35, 38, 41 and 44.~Given IV
Study: NCT03076684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-fructose diet
Description: Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to \<5% of energy and keeping their weight stable.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Subjects in the drug arm will take the drug allopurinol daily.